- Trade rules and agreements can be crucial in determining access to medical technologies. When a trade restriction is not applied correctly or when barriers are put in place in a way which makes it difficult for patients to access technologies, this can have an important impact on the sector. MedTech Europe engages in trade negotiations to ensure access to medical technologies around the globe. This includes working on bilateral EU trade agreements and initiatives (e.g., the EU-US Trade and Technology Council) as well as engaging at the multilateral level on World Trade Organisation (WTO) activities on technical barriers to trade.
- MedTech Europe is also involved in discussions at the level of the World Customs Organization (WCO) to ensure a clear and consistent application of customs rules to medical technologies. The goal is to facilitate trade, explore questions related to tariffs, sanctions, and embargoes, and discuss and revise the classification of devices under the Harmonised System (HS) of tariff.
Our Priorities International
Trade & Customs
As a global industry, trade negotiations and customs rules play an important role in bringing medical technologies to customers and patients around the world. MedTech Europe is actively engaged in trade and customs issues at European and international level.
International regulators, standards and policy-making bodies play a central role in shaping global healthcare. MedTech Europe engages with stakeholders and decision-makers around the world on issues of common interest.
Medical technology companies operate in diverse global markets. Specific insights on regulatory, ethical and procurement environment are essential to expanding to new markets.
Global Health Policy
Through our advocacy efforts, technical expertise, and holistic approach, MedTech Europe actively engages on many international issues of relevance for the medical technology sector.
Brexit is a critical topic for the medical technology industry which has developed highly complex ties between the United Kingdom (UK) and the rest of the EU. Medical technologies are often moved between different EU countries during their production lifecycle and their clinical use. Crucially, up to 30% of our industry’s products have been authorised via UK Notified Bodies (CE marking) and could lose such authorisation overnight in the case of a “cliff edge” Brexit. MedTech Europe is tracking developments closely and has produced a position paper and other relevant documents to help medical technology companies to navigate Brexit.